• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed

    1/11/21 4:08:17 PM ET
    $MGEN
    Medical Specialities
    Health Care
    Get the next $MGEN alert in real time by email
    SC 13G 1 tm212819d1_sc13g.htm SC 13G

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C.  20549
     
     
    SCHEDULE 13G*/
    (Rule 13d-102)
     
     
    Miragen Therapeutics, Inc.
    (Name of Issuer)
     
    Common stock, par value $0.01 per share
    (Title of Class of Securities)
     

    60463E202

    (CUSIP Number)
     

    December 31, 2020

    Date of Event Which Requires Filing of the Statement

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨       Rule 13d-1(b)
    x
          Rule 13d-1(c)
    ¨
           Rule 13d-1(d)

     

     

    */ The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

    CUSIP No. 60463E202 13G Page 2 of 14 Pages

     

     

    1.

     

    NAME OF REPORTING PERSON

     

     

    Citadel Advisors LLC

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)       ¨

    (b)       ¨

     

    3.

     

    SEC USE ONLY

     

     

    4.

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

     

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

     

    5.

     

    SOLE VOTING POWER

    0

     

    6.

     

    SHARED VOTING POWER

     

    420,476 shares

     

     

    7.

     

    SOLE DISPOSITIVE POWER

    0

     

    8.

     

    SHARED DISPOSITIVE POWER

    See Row 6 above

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    See Row 6 above

     

    10.

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES

    CERTAIN SHARES

    ¨

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    9.8%1

     

    12.

     

    TYPE OF REPORTING PERSON

    IA; OO; HC

     

     

    1The percentages reported in this Schedule 13G are based upon approximately 4,308,703 shares of common stock outstanding (comprised of (i) 3,908,158 shares of common stock outstanding as of December 7, 2020 (according to the issuer’s definitive proxy statement as filed with the Securities and Exchange Commission on December 14, 2020), and (ii) approximately 400,545 shares of Common Stock issuable upon the conversion of 13,949 shares of the Issuer’s Series A Non-Voting Convertible Preferred Stock, par value $0.01 per share. The conversion of the non-voting preferred shares is subject to a beneficial ownership limitation equal to 9.9% of the outstanding common stock. Except as described in the preceding sentence, all share numbers for the holdings of the reporting persons reported in this Schedule 13G are as of the opening of the market on January 11, 2021.

     

     

     

     

     

    CUSIP No. 60463E202 13G Page 3 of 14 Pages

     

     

    1.

     

    NAME OF REPORTING PERSON

     

     

    Citadel Advisors Holdings LP

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)       ¨

    (b)       ¨

     

    3.

     

    SEC USE ONLY

     

     

    4.

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

     

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

     

    5.

     

    SOLE VOTING POWER

    0

     

    6.

     

    SHARED VOTING POWER

     

    420,476 shares

     

     

    7.

     

    SOLE DISPOSITIVE POWER

    0

     

    8.

     

    SHARED DISPOSITIVE POWER

    See Row 6 above

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    See Row 6 above

     

    10.

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES

    CERTAIN SHARES

    ¨

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    9.8%

     

    12.

     

    TYPE OF REPORTING PERSON

    PN; HC

     

     

     

     

    CUSIP No. 60463E202 13G Page 4 of 14 Pages

     

     

    1.

     

    NAME OF REPORTING PERSON

     

     

    Citadel GP LLC

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)       ¨

    (b)       ¨

     

    3.

     

    SEC USE ONLY

     

     

    4.

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

     

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

     

    5.

     

    SOLE VOTING POWER

    0

     

    6.

     

    SHARED VOTING POWER

     

    420,476 shares

     

     

    7.

     

    SOLE DISPOSITIVE POWER

    0

     

    8.

     

    SHARED DISPOSITIVE POWER

    See Row 6 above.

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    See Row 6 above.

     

    10.

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES

    CERTAIN SHARES

    ¨

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    9.8%

     

    12.

     

    TYPE OF REPORTING PERSON

    OO; HC

     

     

     

     

    CUSIP No. 60463E202 13G Page 5 of 14 Pages

     

     

    1.

     

    NAME OF REPORTING PERSON

     

     

    Citadel Securities LLC

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)       ¨

    (b)       ¨

     

    3.

     

    SEC USE ONLY

     

     

    4.

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

     

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

     

    5.

     

    SOLE VOTING POWER

    0

     

    6.

     

    SHARED VOTING POWER

     

    5,977 shares

     

     

    7.

     

    SOLE DISPOSITIVE POWER

    0

     

    8.

     

    SHARED DISPOSITIVE POWER

    See Row 6 above.

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    See Row 6 above.

     

    10.

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES

    CERTAIN SHARES

    ¨

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0.1%

     

    12.

     

    TYPE OF REPORTING PERSON

    BD, OO

     

     

     

     

    CUSIP No. 60463E202 13G Page 6 of 14 Pages

     

     

    1.

     

    NAME OF REPORTING PERSON

     

     

    CALC IV LP

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)       ¨

    (b)       ¨

     

    3.

     

    SEC USE ONLY

     

     

    4.

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

     

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

     

    5.

     

    SOLE VOTING POWER

    0

     

    6.

     

    SHARED VOTING POWER

     

    6,086 shares

     

     

    7.

     

    SOLE DISPOSITIVE POWER

    0

     

    8.

     

    SHARED DISPOSITIVE POWER

    See Row 6 above.

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    See Row 6 above.

     

    10.

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES

    CERTAIN SHARES

    ¨

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0.1%

     

    12.

     

    TYPE OF REPORTING PERSON

    PN; HC

     

     

     

     

    CUSIP No. 60463E202 13G Page 7 of 14 Pages

     

     

    1.

     

    NAME OF REPORTING PERSON

     

     

    Citadel Securities GP LLC

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)       ¨

    (b)       ¨

     

    3.

     

    SEC USE ONLY

     

     

    4.

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

     

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

     

    5.

     

    SOLE VOTING POWER

    0

     

    6.

     

    SHARED VOTING POWER

     

    6,086 shares

     

     

    7.

     

    SOLE DISPOSITIVE POWER

    0

     

    8.

     

    SHARED DISPOSITIVE POWER

    See Row 6 above.

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    See Row 6 above.

     

    10.

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES

    CERTAIN SHARES

    ¨

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0.1%

     

    12.

     

    TYPE OF REPORTING PERSON

    OO; HC

     

     

     

     

    CUSIP No. 60463E202 13G Page 8 of 14 Pages

     

     

    1.

     

    NAME OF REPORTING PERSON

     

     

    Kenneth Griffin

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)       ¨

    (b)       ¨

     

    3.

     

    SEC USE ONLY

     

     

    4.

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

    U.S. Citizen

     

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

     

    5.

     

    SOLE VOTING POWER

    0

     

    6.

     

    SHARED VOTING POWER

     

    426,562 shares

     

     

    7.

     

    SOLE DISPOSITIVE POWER

    0

     

    8.

     

    SHARED DISPOSITIVE POWER

    See Row 6 above

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    See Row 6 above

     

    10.

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES

    CERTAIN SHARES

    ¨

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    9.9%

     

    12.

     

    TYPE OF REPORTING PERSON

    IN; HC

     

     

     

     

    CUSIP No. 60463E202 13G Page 9 of 14 Pages

     

    Item 1(a)Name of Issuer
      
     Miragen Therapeutics, Inc.
      
    Item 1(b)Address of Issuer’s Principal Executive Offices
      
     6200 Lookout Rd., Boulder CO, 80301

      

    Item 2(a)Name of Person Filing

    This Schedule 13G is being jointly filed by Citadel Advisors LLC (“Citadel Advisors”), Citadel Advisors Holdings LP (“CAH”), Citadel GP LLC (“CGP”), Citadel Securities LLC (“Citadel Securities”), CALC IV LP (“CALC4”), Citadel Securities GP LLC (“CSGP”) and Mr. Kenneth Griffin (collectively with Citadel Advisors, CAH, CGP, Citadel Securities, CALC4 and CSGP, the “Reporting Persons”) with respect to shares of common stock (and other securities convertible into common stock) of the above-named issuer owned by Citadel Multi-Strategy Equities Master Fund Ltd., a Cayman Islands limited company (“CM”), Citadel Securities and CRBU Holdings LLC, a Delaware limited liability company (“CRBH”).
      
     Citadel Advisors is the portfolio manager for CM. CAH is the sole member of Citadel Advisors. CGP is the general partner of CAH. CALC4 is the non-member manager of Citadel Securities and CRBH. CSGP is the general partner of CALC4. Mr. Griffin is the President and Chief Executive Officer of CGP, and owns a controlling interest in CGP and CSGP.
      
     The filing of this statement shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any securities covered by the statement other than the securities actually owned by such person (if any).

     

    Item 2(b)Address of Principal Business Office

    The address of the principal business office of each of the Reporting Persons is 131 S. Dearborn Street, 32nd Floor, Chicago, Illinois 60603.

     

    Item 2(c)Citizenship

    Each of Citadel Advisors, CGP, Citadel Securities and CSGP is organized as a limited liability company under the laws of the State of Delaware. Each of CALC4 and CAH is organized as a limited partnership under the laws of the State of Delaware. Mr. Griffin is a U.S. citizen.
      
    Item 2(d)Title of Class of Securities
      
     Common stock, par value $0.01 per share
      
    Item 2(e)CUSIP Number
      
     60463E202

     

     

     

     

    CUSIP No. 60463E202 13G Page 10 of 14 Pages

     

    Item 3If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

     

    (a)¨ Broker or dealer registered under Section 15 of the Exchange Act;

     

    (b)¨ Bank as defined in Section 3(a)(6) of the Exchange Act;

     

    (c)¨ Insurance company as defined in Section 3(a)(19) of the Exchange Act;

     

    (d)¨ Investment company registered under Section 8 of the Investment Company Act;

     

    (e)¨ An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);

     

    (f)¨ An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

     

    (g)¨ A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

     

    (h)¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

     

    (i)¨ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

     

    (j)¨ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);

     

    (k)¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: ____________.

     

     

     

     

    CUSIP No. 60463E202 13G Page 11 of 14 Pages

     

    Item 4Ownership

     

    A.Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC

     

    (a)Each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC may be deemed to beneficially own 420,476 shares of common stock.

     

    (b)The number of shares each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC may be deemed to beneficially own constitutes approximately 9.8% of the common stock outstanding.

     

    (c)Number of shares as to which such person has:

     

    (i)sole power to vote or to direct the vote: 0

     

    (ii)shared power to vote or to direct the vote: 420,476

     

    (iii)sole power to dispose or to direct the disposition of: 0

     

    (iv)shared power to dispose or to direct the disposition of: 420,476

     

    B.Citadel Securities LLC

     

    (a)Citadel Securities LLC may be deemed to beneficially own 5,977 shares of common stock.

     

    (b)The number of shares that Citadel Securities LLC may be deemed to beneficially own constitutes approximately 0.1% of the common stock outstanding.

     

    (c)Number of shares as to which such person has:

     

    (i)sole power to vote or to direct the vote: 0

     

    (ii)shared power to vote or to direct the vote: 5,977

     

    (iii)sole power to dispose or to direct the disposition of: 0

     

    (iv)shared power to dispose or to direct the disposition of: 5,977

     

    C.CALC IV LP and Citadel Securities GP LLC

     

    (a)Each of CALC IV LP and Citadel Securities GP LLC may be deemed to beneficially own 6,086 shares of common stock.

     

    (b)The number of shares that each of CALC IV LP and Citadel Securities GP LLC may be deemed to beneficially own constitutes approximately 0.1% of the common stock outstanding.

     

     

     

     

    CUSIP No. 60463E202 13G Page 12 of 14 Pages

     

    (c)Number of shares as to which such person has:

     

    (i)sole power to vote or to direct the vote: 0

     

    (ii)shared power to vote or to direct the vote: 6,086

     

    (iii)sole power to dispose or to direct the disposition of: 0

     

    (iv)shared power to dispose or to direct the disposition of: 6,086

     

    D.Kenneth Griffin

     

    (a)Mr. Griffin may be deemed to beneficially own 426,562 shares of common stock.

     

    (b)The number of shares that Mr. Griffin may be deemed to beneficially own constitutes approximately 9.9% of the common stock outstanding.

     

    (c)Number of shares as to which such person has:

     

    (i)sole power to vote or to direct the vote: 0

     

    (ii)shared power to vote or to direct the vote: 426,562

     

    (iii)sole power to dispose or to direct the disposition of: 0

     

    (iv)shared power to dispose or to direct the disposition of: 426,562

     

     

     

     

    CUSIP No. 60463E202 13G Page 13 of 14 Pages

     

    Item 5Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ¨.

     

    Item 6Ownership of More than Five Percent on Behalf of Another Person

     

    Not Applicable

     

    Item 7Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company

     

    See Item 2 above

     

    Item 8Identification and Classification of Members of the Group

     

    Not Applicable

     

    Item 9Notice of Dissolution of Group

     

    Not Applicable

     

    Item 10Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

    CUSIP No. 60463E202 13G Page 14 of 14 Pages

     

    After reasonable inquiry and to the best of its knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

      

    Dated this 11th day of January, 2021.

     

    CITADEL SECURITIES LLC       CITADEL ADVISORS LLC    
         
         
    By: /s/ Guy Miller   By: /s/ Noah Goldberg
      Guy Miller, Authorized Signatory     Noah Goldberg, Authorized Signatory
         
         
    CALC IV LP   CITADEL ADVISORS HOLDINGS LP
         
         
    By: /s/ Guy Miller   By: /s/ Noah Goldberg
      Guy Miller, Authorized Signatory     Noah Goldberg, Authorized Signatory
         
         
    CITADEL SECURITIES GP LLC   CITADEL GP LLC
         
         
    By: /s/ Guy Miller   By: /s/ Noah Goldberg
      Guy Miller, Authorized Signatory     Noah Goldberg, Authorized Signatory
         
         
        KENNETH GRIFFIN
         
        By: /s/ Noah Goldberg
          Noah Goldberg, attorney-in-fact*

     

     

    *Noah Goldberg is signing on behalf of Kenneth Griffin as attorney-in-fact pursuant to a power of attorney previously filed with the Securities and Exchange Commission, and hereby incorporated by reference herein. The power of attorney was filed as an attachment to a filing by Citadel Advisors LLC on Schedule 13G for Zentalis Pharmaceuticals Inc. on April 9, 2020.

     

     

     

     

    Get the next $MGEN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MGEN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MGEN
    SEC Filings

    View All

    SEC Form 8-K filed

    8-K - Viridian Therapeutics, Inc.\DE (0001590750) (Filer)

    1/20/21 8:01:58 AM ET
    $MGEN
    Medical Specialities
    Health Care

    SEC Form SC 13G filed

    SC 13G - Viridian Therapeutics, Inc.\DE (0001590750) (Subject)

    1/19/21 4:18:23 PM ET
    $MGEN
    Medical Specialities
    Health Care

    SEC Form 4 filed by Stuart William Marshall

    4 - MIRAGEN THERAPEUTICS, INC. (0001590750) (Issuer)

    1/15/21 7:47:57 PM ET
    $MGEN
    Medical Specialities
    Health Care

    $MGEN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by L Joseph Turner

    4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)

    2/8/21 5:41:03 PM ET
    $MGEN
    Medical Specialities
    Health Care

    SEC Form 4 filed by Evan Peter Harwin

    4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)

    2/8/21 5:40:19 PM ET
    $MGEN
    Medical Specialities
    Health Care

    SEC Form 4 filed by S. Jeffrey Hatfield

    4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)

    2/8/21 5:40:28 PM ET
    $MGEN
    Medical Specialities
    Health Care

    $MGEN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    miRagen Therapeutics Announces Company Name Change to Viridian Therapeutics and New Executive Appointments, Including Expansion of Leadership Team

    Jonathan Violin, Ph.D., M.B.A. appointed President, CEO and director Barrett Katz, M.D., M.B.A. joins Viridian as Chief Medical OfficerViridian is developing VRDN-001 and VRDN-002 for the treatment of thyroid eye diseaseCompany recently licensed exclusive rights from Xencor, Inc. to develop and commercialize therapeutic antibodies targeting IGF-1R incorporating Xtend™ Fc half-life extension technology BOULDER, Colo., Jan. 19, 2021 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a development-stage biotechnology company, today announced its name change to Viridian Therapeutics, Inc. (“Viridian”).   Beginning tomorrow, Viridian will trade on NASDAQ under the ticker symbol "VR

    1/19/21 7:00:00 AM ET
    $MGEN
    Medical Specialities
    Health Care

    miRagen Enters into License Agreement with Xencor for use of Xtend™ Antibody Technology for Investigational Antibodies to Treat Thyroid Eye Disease

    Company obtains exclusive rights to develop and commercialize antibody therapeutics targeting insulin-like growth factor-1 receptor (IGF-1R) using Xencor’s Xtend™ half-life extension technology miRagen expects to file an Investigational New Drug (IND) application for VRDN-002, including half-life extension, by the end of 2021 BOULDER, Colo., Dec. 17, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a development-stage biotechnology company, today announced an agreement under which miRagen gains exclusive rights to develop and commercialize therapeutic antibodies targeting IGF-1R incorporating Xtend™ Fc technology from Xencor, Inc. This clinically validated technology p

    12/17/20 7:00:00 AM ET
    $MGEN
    Medical Specialities
    Health Care

    $MGEN
    Leadership Updates

    Live Leadership Updates

    View All

    miRagen Therapeutics Announces Company Name Change to Viridian Therapeutics and New Executive Appointments, Including Expansion of Leadership Team

    Jonathan Violin, Ph.D., M.B.A. appointed President, CEO and director Barrett Katz, M.D., M.B.A. joins Viridian as Chief Medical OfficerViridian is developing VRDN-001 and VRDN-002 for the treatment of thyroid eye diseaseCompany recently licensed exclusive rights from Xencor, Inc. to develop and commercialize therapeutic antibodies targeting IGF-1R incorporating Xtend™ Fc half-life extension technology BOULDER, Colo., Jan. 19, 2021 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a development-stage biotechnology company, today announced its name change to Viridian Therapeutics, Inc. (“Viridian”).   Beginning tomorrow, Viridian will trade on NASDAQ under the ticker symbol "VR

    1/19/21 7:00:00 AM ET
    $MGEN
    Medical Specialities
    Health Care

    $MGEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Miragen Therapeutics, Inc.

    SC 13G/A - Viridian Therapeutics, Inc.\DE (0001590750) (Subject)

    3/15/21 4:38:22 PM ET
    $MGEN
    Medical Specialities
    Health Care

    SEC Form SC 13G filed

    SC 13G - Viridian Therapeutics, Inc.\DE (0001590750) (Subject)

    3/10/21 7:17:41 AM ET
    $MGEN
    Medical Specialities
    Health Care

    SEC Form SC 13G filed

    SC 13G - Viridian Therapeutics, Inc.\DE (0001590750) (Subject)

    2/19/21 8:02:11 AM ET
    $MGEN
    Medical Specialities
    Health Care